Presentation α線放出核種211Atを用いた放射免疫療法

李, 惠子  ,  長谷川, 純崇  ,  永津, 弘太郎  ,  佐賀, 恒夫

【Objective】Astatine 211 (211At, T1/2=7.21h) is one of the attractive alpha emitter as it belongs to the same family as iodine, and the application into radioimmunotherapy (211At-RIT) is expected. We evaluated the biological effects of 211At-RIT both in vitro and in vivo.【Methods】211At was labeled with trastuzumab, anti-HER2 monoclonal antibody, using N-succinimidyl-3-(trimethylstannyl)benzoate. The in vitro cytotoxicity was evaluated by cell growth assay using a human metastatic gastric cancer cell line overexpressing HER2 protein. 211At-labeled trastuzumab, 0.5-2.5 MBq, was injected into mice bearing gastric cancer xenografts to determine the anti-tumor effect in vivo.【Results】211At-labeled trastuzumab showed significant cytotoxicity in vitro and suppressed tumor growth in vivo.【Conclusion】211At-RIT could be an effective treatment to HER2 overexpressing gastric cancer.

Number of accesses :  

Other information